Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1224860

Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience


Perković, Dijana; Petrić, Marin; Božić, Ivona; Borić, Katarina; Marasović Krstulović, Daniela; Radić, Mislav; Martinović Kaliterna, Dušanka
Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience // Wiener klinische Wochenschrift, 133 (2021), 19-20; 1070-1075 doi:10.1007/s00508-020-01669-y (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1224860 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience

Autori
Perković, Dijana ; Petrić, Marin ; Božić, Ivona ; Borić, Katarina ; Marasović Krstulović, Daniela ; Radić, Mislav ; Martinović Kaliterna, Dušanka

Izvornik
Wiener klinische Wochenschrift (0043-5325) 133 (2021), 19-20; 1070-1075

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Fibrosis, pulmonary ; Immunotherapy ; Interstitial lung diseases ; Skin (digital) ulcers ; Treatment outcome

Sažetak
Aim: Systemic sclerosis (SSc) is a rare chronic disease characterized by pathologic collagen deposits in the skin and internal organs. Although it is considered to be an autoimmune disease, immunosuppressants have a limited effect on severe SSc. Intravenous immunoglobulins (IVIG) have shown favorable effects in patients with SSc by suppressing the action of profibrotic cytokines, so they could have additional effect on standard treatment such as cyclophosphamide (CYC). This article presents the immunomodulatory effect of low-dose IVIG in addition to CYC in the treatment of severe SSc in this center during the last 9 years. Methods: This retrospective observational study analyzed the medical documentation of nine patients with SSc treated with low-dose IVIG (0.4 g/kg and month) together with intravenous CYC (600 mg/m2 and month). The therapeutic effect on lung and skin manifestations was assessed. Results: Of the patients one had interstitial lung diseases (ILD), two had progressive skin diseases, and six had a combination of skin and lung involvement. The best results were achieved in skin changes, where complete healing of digital ulcers (DU) was recorded in every reported case. A decrease in the modified Rodnan skin score (mRSS) was noted in three patients and increased diffusion capacity of the lungs for carbon monoxide in another three patients. Conclusion: The results of the study suggest that IVIG may be an additional treatment option together with CYC for patients for whom other therapies have failed, but further studies on the exact role of IVIG in the treatment of severe SSc are required.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Ustanove:
KBC Split,
Medicinski fakultet, Split

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Perković, Dijana; Petrić, Marin; Božić, Ivona; Borić, Katarina; Marasović Krstulović, Daniela; Radić, Mislav; Martinović Kaliterna, Dušanka
Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience // Wiener klinische Wochenschrift, 133 (2021), 19-20; 1070-1075 doi:10.1007/s00508-020-01669-y (međunarodna recenzija, članak, znanstveni)
Perković, D., Petrić, M., Božić, I., Borić, K., Marasović Krstulović, D., Radić, M. & Martinović Kaliterna, D. (2021) Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience. Wiener klinische Wochenschrift, 133 (19-20), 1070-1075 doi:10.1007/s00508-020-01669-y.
@article{article, author = {Perkovi\'{c}, Dijana and Petri\'{c}, Marin and Bo\v{z}i\'{c}, Ivona and Bori\'{c}, Katarina and Marasovi\'{c} Krstulovi\'{c}, Daniela and Radi\'{c}, Mislav and Martinovi\'{c} Kaliterna, Du\v{s}anka}, year = {2021}, pages = {1070-1075}, DOI = {10.1007/s00508-020-01669-y}, keywords = {Fibrosis, pulmonary, Immunotherapy, Interstitial lung diseases, Skin (digital) ulcers, Treatment outcome}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-020-01669-y}, volume = {133}, number = {19-20}, issn = {0043-5325}, title = {Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience}, keyword = {Fibrosis, pulmonary, Immunotherapy, Interstitial lung diseases, Skin (digital) ulcers, Treatment outcome} }
@article{article, author = {Perkovi\'{c}, Dijana and Petri\'{c}, Marin and Bo\v{z}i\'{c}, Ivona and Bori\'{c}, Katarina and Marasovi\'{c} Krstulovi\'{c}, Daniela and Radi\'{c}, Mislav and Martinovi\'{c} Kaliterna, Du\v{s}anka}, year = {2021}, pages = {1070-1075}, DOI = {10.1007/s00508-020-01669-y}, keywords = {Fibrosis, pulmonary, Immunotherapy, Interstitial lung diseases, Skin (digital) ulcers, Treatment outcome}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-020-01669-y}, volume = {133}, number = {19-20}, issn = {0043-5325}, title = {Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience}, keyword = {Fibrosis, pulmonary, Immunotherapy, Interstitial lung diseases, Skin (digital) ulcers, Treatment outcome} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font